Uncategorized

In a new study, Harris, et al., investigated the potential health impact and cost-effectiveness of the M72/AS01E vaccine in two high burden TB countries: India and South Africa

A recent paper by Foix, et al., has reported on the potential of existing strains of SARS-CoV-2, and future variants to escape the immune system's cytotoxic T cell response.

In a recent paper, Ziyang, et al., have produced novel insights into and further developed an HIV vaccine through the use of a unique trimer in order to develop Tier-2 neutralizing antibodies...

In a recent study, researchers have demonstrated that the SARS-CoV-2 receptor-binding domain (RBD)-based, sortase A-conjugated nanoparticle (RBD-scNP) vaccine induces neutralizing antibodies (NAbs) in non-human primates (NHPs) against all eight variants of SARS-CoV-2.

In a recent study published in Science, Melani, et al., have reported on a several families of proteins in the body that may be used as a tool to predict which patients may be susceptible to rejection of a new organ transplant. This has the potential to aid clinicians in making informed decisions with regards to treatments.

For decades, researchers have suspected that patients infected with a common virus, Epstein-Barr (EVB), might be more likely to develop multiple sclerosis. Now, a team led by Harvard University researchers reports what some say is the most compelling evidence yet of a strong link between these two diseases.

In a recent paper, Chong, et al., investigated the effect of IFN-λ on SARS-CoV-2 infection in mice. They found that IFN-λ conferred protection against the SARS-CoV-2 B.1.351 (Beta variant) and the newer SARS-CoV-2 B.1.1.529 (Omicron variant).

In a recent study, Wilson, et al., have described how Th17 cell promote the onset of certain autoimmune diseases such as multiple sclerosis (MS). The researchers have discovered a mechanism used by Th17 to fulfil its function within the immune system - neutrophil extracellular traps (NETs).

In a recent paper, results published in The Lancet from a clinical trial has reported that through the administration of peanut oral immunotherapy in children, ages 1-3, who are extremely allergic to peanuts, safely desensitized most of them and induced remission of peanut allergy in one-fifth.

A new study by Bojkova, et al., reported on the SARS-CoV-2 Omicron variant and why it is less efficient than the Delta variant at inhibiting/blocking the host cellular defense mechanism against viruses. This defense mechanism of interest is the “interferon response.”